Eli Lilly Acquires AtaiBeckley

Eli Lilly to Acquire Vaccine Company for Up to $1.55 Billion

May 27, 2026

Biotechnology

Vaccine Company, Inc. announced it has entered into a definitive agreement to be acquired by Eli Lilly and Company in a deal valued at up to $1.55 billion, including upfront and milestone-based payments. The acquisition is intended to accelerate development of Vaccine Company’s next-generation in vivo nanoparticle (IVN) vaccine platform, led by a Phase 1-ready Epstein-Barr virus (EBV) vaccine candidate targeting infectious mononucleosis and longer-term EBV-linked diseases.

Eli Lilly and Company to Acquire Ajax Therapeutics, Inc.

April 27, 2026

Pharmaceuticals

Eli Lilly and Company announced a definitive agreement to acquire Ajax Therapeutics, Inc. in a deal valued at up to $2.3 billion, including upfront and milestone-based payments. The acquisition is intended to expand Lilly’s oncology pipeline with Ajax’s lead candidate, AJ1-11095, a Type II JAK2 inhibitor in Phase 1 development for myelofibrosis, including patients previously treated with Type I JAK2 inhibitors.

Eli Lilly Acquires Adverum Biotechnologies

December 9, 2025

Biotechnology

Eli Lilly and Company agreed to acquire Adverum Biotechnologies in a cash-and-contingent-value-rights tender offer for all outstanding shares. The total consideration is $3.56 per share in cash at closing plus a CVR that could pay up to $8.91 per share upon achievement of specified milestones, with the transaction expected to close in the fourth quarter of 2025.

Eli Lilly Acquires POINT Biopharma Global

December 27, 2023

Biotechnology

Eli Lilly and Company completed the acquisition of POINT Biopharma Global Inc. after a tender offer at $12.50 per share in cash, followed by a second-step merger and delisting of POINT's common stock. The transaction brings POINT's radioligand therapy pipeline and radiopharmaceutical capabilities into Lilly's oncology research and development efforts.

Beckley Psytech Acquires Eleusis Therapeutics Limited

October 24, 2022

Biotechnology

Beckley Psytech Limited has acquired 100% of Eleusis Therapeutics Limited in an all-equity transaction, adding Eleusis' clinical-stage assets (including ELE-101) and its R&D team to Beckley's pipeline. Eleusis CEO Shlomi Raz will join Beckley as Chief Business Officer as the companies integrate to accelerate development of short-duration psychedelic therapies.

Eli Lilly and Company to Acquire Prevail Therapeutics

December 15, 2020

Biotechnology

Eli Lilly and Company announced a definitive agreement to acquire Prevail Therapeutics for $22.50 per share in cash, plus a non-tradable contingent value right (CVR) worth up to $4.00 per share, for total consideration of up to approximately $1.04 billion. The acquisition is intended to establish a gene therapy program within Lilly anchored by Prevail’s AAV9-based neuroscience pipeline. Lilly expects the transaction to close in the first quarter of 2021, subject to customary closing conditions and regulatory approvals.